Lonza adds biologics capacity with $1.2bn Roche deal

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match capacity with pipeline requirements.